OverviewChartProfileKey statisticsFinancialsTechnicalNews
Derivatives
TraderScreen

MORPHOSYS AG O.N./  DE0006632003  /

Xetra
30/07/2024  14:56:18 Chg. +0.05 Volume Bid15:04:18 Ask15:00:01 Market Capitalization Dividend Y. P/E Ratio
67.90EUR +0.07% 4,802
Turnover: 326,275.70		 67.90Bid Size: 2,839 68.00Ask Size: 1,593 2.56 bill.EUR - -
TeleTrader 11/04 Novartis launches offer for Morphosys at €68 per share
TeleTrader 12/03 Germany clears Novartis' MorphoSys $2.9B deal
TeleTrader 05/02 Novartis to acquire MorphoSys for $2.9B
GlobeNewswire 03/06/2021 CONSTELLATION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CNST and Encourages Investors ...
GlobeNewswire 02/06/2021 Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
GlobeNewswire 27/04/2020 I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Mu...
GlobeNewswire 28/10/2019 MOR106 clinical development in atopic dermatitis stopped for futility
GlobeNewswire 23/04/2019 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire 23/04/2019 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...
GlobeNewswire 13/09/2018 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire 13/09/2018 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
GlobeNewswire 12/09/2018 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire 12/09/2018 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...
GlobeNewswire 19/07/2018 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire 19/07/2018 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
GlobeNewswire 01/05/2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire 01/05/2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...
GlobeNewswire 19/04/2018 Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market
GlobeNewswire 17/02/2018 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire 17/02/2018 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...
GlobeNewswire 27/09/2017 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...
GlobeNewswire 27/09/2017 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...
GlobeNewswire 31/08/2017 Aptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/E...
GlobeNewswire 15/12/2016 Aptevo Therapeutics Amends Collaboration Agreement with MorphoSys AG for Novel Immunotherapeutic, MO...
GlobeNewswire 13/12/2016 MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...